Cereno Scientific (CRNO) investor relations material

Strategic focus and business development

• Pioneering epigenetic modulation drugs targeting rare cardiovascular and lung diseases, aiming to slow, halt, or reverse disease progression and improve patient outcomes.

• Operating with a small core team and extensive global collaborations, including a U.S. subsidiary and partnerships with major institutions.

• Achieved significant growth since 2016, uplisting to NASDAQ and expanding the investor base without venture capital backing.

• Actively pursuing business development, including potential deals with large pharmaceutical companies.

Pipeline progress and clinical development

• Advancing three programs: CS1 (repurposed drug for pulmonary arterial hypertension), CSO-14 (new chemical entity for fibrotic lung diseases), and CSO-585 (licensed from University of Michigan).

• CS1 completed Phase IIa with positive safety and efficacy signals; extended access program underway with a 12-month readout expected in Q1.

• CSO-14 completed Phase I with favorable safety and exposure; Phase II trial planned for next year.

• Both CS1 and CSO-14 are expected to enter Phase II trials globally, with CS1's Phase IIb involving 100–150 patients across 40–50 sites.

Regulatory and market positioning

• Received FDA Fast Track designation for CS1, enhancing regulatory support, investor confidence, and development speed.

• Drugs are designed to be oral, well-tolerated, and additive to current therapies, targeting significant unmet needs in rare diseases.

• Financing achieved through debt and share issues, with ongoing growth in market cap and investor numbers.

• Prepared to fund trials independently or through partnerships, with flexibility for future collaborations.